Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$170.80
-0.1%
$161.68
$111.09
$183.00
$10.43B0.37494,434 shs369,830 shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.67
-2.5%
$26.29
$23.15
$139.92
$10.31B1.868.41 million shs7.15 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$56.37
+0.1%
$46.72
$30.67
$60.60
$3.49B2.25896,197 shs985,411 shs
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$15.80
-2.3%
$14.17
$12.26
$16.89
$13.19B0.331.51 million shs1.69 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-1.31%+8.42%+11.65%+30.11%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-2.88%+12.77%-22.96%-81.95%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%+3.66%+26.93%+2.90%+65.94%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.00%+1.66%+9.78%+24.45%+10.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.3759 of 5 stars
4.53.00.00.02.21.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.4523 of 5 stars
4.02.00.04.61.42.51.3
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
1.9774 of 5 stars
2.52.00.00.02.12.51.3
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
1.3448 of 5 stars
1.53.01.70.02.50.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$220.6729.20% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6174.77% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$65.4416.10% Upside
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
3.00
Buy$16.957.29% Upside

Current Analyst Ratings Breakdown

Latest PTGX, RDY, MRNA, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$215.00 ➝ $224.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/5/2025
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/5/2025
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$14.44 ➝ $16.90
6/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$196.00 ➝ $201.00
6/3/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/19/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
5/5/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$368.70M28.30N/AN/A($1.88) per share-90.85
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.29N/AN/A$28.33 per share0.94
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$207.80M16.81N/AN/A$5.84 per share9.65
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$325.54B0.04$1.19 per share13.25$4.50 per share3.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A711.67N/A-104.54%N/A-39.23%9/2/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-110.04%-28.74%-21.83%7/30/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$78.96M$0.7521.19N/AN/A52.76%34.68%30.98%8/5/2025 (Estimated)
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$668M$0.6625.1619.27N/A17.25%17.87%12.32%7/25/2025 (Estimated)

Latest PTGX, RDY, MRNA, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q4 24/25
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million
5/6/2025Q1 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.080.51%N/A12.12%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.17
0.84
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
10.69
10.70
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.02
1.92
1.38

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4.90%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
64061.09 million36.41 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.74 million324.40 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12061.98 million56.38 millionOptionable
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
24,800834.77 million818.05 millionOptionable

Recent News About These Companies

Dr. Reddy’s Labs ADR Stock Price History

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$170.80 -0.12 (-0.07%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$170.86 +0.06 (+0.04%)
As of 06/13/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.67 -0.68 (-2.49%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$26.66 -0.01 (-0.02%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$56.37 +0.05 (+0.09%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$56.40 +0.03 (+0.04%)
As of 06/13/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$15.80 -0.37 (-2.30%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$15.78 -0.01 (-0.08%)
As of 06/13/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.